134 related articles for article (PubMed ID: 26429174)
1. Histological and immunohistochemical aspects of papillary thyroid cancer.
Radu TG; Mogoantă L; Busuioc CJ; Stănescu C; Grosu F
Rom J Morphol Embryol; 2015; 56(2 Suppl):789-95. PubMed ID: 26429174
[TBL] [Abstract][Full Text] [Related]
2. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins.
Mseddi M; Ben Mansour R; Gouiia N; Mnif F; Bousselaa R; Abid M; Boudaouara T; Attia H; Lassoued S
Adv Med Sci; 2017 Mar; 62(1):45-51. PubMed ID: 28187375
[TBL] [Abstract][Full Text] [Related]
4. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
7. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
8. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
10. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
11. [The expression and clinical significance of EphA2 and E-cadherin in papillary thyroid carcinoma].
Liu Y; Miao Y; Li X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jun; 29(11):1020-3. PubMed ID: 26536708
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Gardovskis J
Langenbecks Arch Surg; 2010 Sep; 395(7):885-91. PubMed ID: 20640858
[TBL] [Abstract][Full Text] [Related]
13. Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer.
Ali KM; Awny S; Ibrahim DA; Metwally IH; Hamdy O; Refky B; Abdallah A; Abdelwahab K
Ann Diagn Pathol; 2019 Jun; 40():59-65. PubMed ID: 31031216
[TBL] [Abstract][Full Text] [Related]
14. Co-expression and clinical utility of Snail and N-cadherin in papillary thyroid carcinoma.
Yang X; Shi R; Zhang J
Tumour Biol; 2016 Jan; 37(1):413-7. PubMed ID: 26219900
[TBL] [Abstract][Full Text] [Related]
15. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
16. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
Preto A; Reis-Filho JS; Ricardo S; Soares P
Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
[TBL] [Abstract][Full Text] [Related]
17. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.
Wiseman SM; Griffith OL; Deen S; Rajput A; Masoudi H; Gilks B; Goldstein L; Gown A; Jones SJ
Arch Surg; 2007 Aug; 142(8):717-27; discussion 727-9. PubMed ID: 17709725
[TBL] [Abstract][Full Text] [Related]
18. Novel BRAF and KRAS Mutations in Papillary Thyroid Carcinoma Arising in Struma Ovarii.
Tan A; Stewart CJ; Garrett KL; Rye M; Cohen PA
Endocr Pathol; 2015 Dec; 26(4):296-301. PubMed ID: 26362194
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study.
Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S
J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]